Dedifferentiated Liposarcoma: Expert Insights and CME Activity скачать в хорошем качестве

Dedifferentiated Liposarcoma: Expert Insights and CME Activity

Claim your CME/AAPA credit here: https://bit.ly/3xXotjt Click the links below for the Task Force activity! Accredited CME/AAPA Podcast: https://i3health.com/course-informati... Position Statement Published in Cancer Treatment Reviews: https://www.cancertreatmentreviews.co... Live Task Force:    • Dedifferentiated Liposarcoma Multidiscipli...   In this exclusive interview, Dr. Richard Riedel (Duke Cancer Institute) and Dr. Candace Haddox (Dana-Farber Cancer Institute) share their expertise on dedifferentiated liposarcoma (DDLPS) as part of i3 Health’s CME Task Force activity. Explore the complexities of this rare sarcoma subtype, including its molecular landscape, emerging therapies, and key clinical trials like STRASS 2, BRIGHTLINE-1, and SARC041. Follow us here: Facebook   / i3health   Instagram   / i3health   Linkedin   / i3health   Soundcloud   / i3-health   X   / i3health   STATEMENT OF NEED Dedifferentiated liposarcoma (DDLPS) is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes DDLPS from other types of undifferentiated sarcomas. Diagnosis of DDLPS remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). Currently, surgical resection with or without radiation is the mainstay of treatment for localized disease, and anthracycline-based therapy is a standard first-line treatment for advanced disease. Numerous novel therapies are currently under investigation, including CDK4/6 inhibitors, MDM2-p53 pathway inhibitors, and immunotherapies, with the potential to transform the treatment landscape for DDLPS (Nishio et al, 2021). Due to the complex management of DDLPS, collaboration of the multidisciplinary health care team, including medical oncologists, surgical oncologists, radiation oncologists, and pathologists, is crucial. This Dedifferentiated Liposarcoma Task Force podcast will provide a consensus opinion on the optimal diagnosis, treatment, and management of this disease. It features perspectives from Task Force co-chairs Richard F. Riedel, MD, Associate Professor in the Division of Medical Oncology at Duke University Medical Center, and Candace L. Haddox, MD, Physician at Dana-Farber Cancer Institute and Instructor in Medicine at Harvard Medical School. DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Richard F. Riedel, MD, discloses that he has received grants/research support from Aadi Bioscience, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, NanoCarrier, Oncternal, PTC Therapeutics, SARC, SpringWorks, TRACON, and Trillium; and that he has served as a consultant or on an advisory board/panel for Aadi Bioscience, Adaptimmune, Bayer, Blueprint, Boehringer Inhelheim, Daiichi-Sankyo, Decipheral, GlaxoSmithKline, NanoCarrier, and SpringWorks. Candace L. Haddox, MD, discloses that she has served as a consultant or on an advisory/board panel for Aadi Bioscience; and that she has received grants/research support from Aadi Bioscience, EMD Serono, Cogent, HiFiBio, Roche, and Tango Therapeutics. i3 Health has mitigated all relevant financial relationships. #SarcomaAwarenessMonth #DDLPS #SarcomaCare #CMEActivity #OncologyEducation #TargetedTherapies #ClinicalTrials #SoftTissueSarcoma #CancerResearch #PatientAdvocacy